Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs FuelCell Energy Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while FuelCell Energy Inc trades at $20.65 (market cap $1.68B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 23.7× FuelCell Energy Inc's market cap, and FuelCell Energy Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FCEL | |
|---|---|---|
Market Cap | $39.89B | $1.68B |
Sector | Health | Industrials |
52-Week High | $491.22 | $36.01 |
52-Week Low | $278.09 | $3.92 |
Enterprise Value | $38.15B | $1.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
FuelCell Energy (FCEL) trades at $21.03, down 8.57% amid recent volatility from a $225 million stock offering. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company continues to report losses with a net income margin of -132.41% in 2025, though revenue grew to $158.16 million. Recent news highlights a strategic partnership with Siemens to scale clean power solutions for data centers, a key growth area representing 90% of its sales pipeline.
FCEL presents a high-risk, high-reward opportunity driven by AI data center demand and new partnerships, but persistent profitability challenges and shareholder dilution from recent financing pose significant risks. Analyst consensus is mixed with a $20.13 price target, suggesting cautious optimism amid ongoing operational losses and competitive pressures in the fuel cell sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
